Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,687 result(s) found for: placebo. Displaying page 239 of 635.
    «« First « Previous 235  236  237  238  239  240  241  242  243  Next» Last»»
    EudraCT Number: 2014-003492-36 Sponsor Protocol Number: PS0003 Start Date*: 2015-03-12
    Sponsor Name:UCB Biopharma, SPRL
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- And Active-Controlled Study Followed By A Placebo-Controlled Maintenance Period And Open-Label Follow-Up To Evaluate The E...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018190 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) CZ (Completed) NL (Completed) PL (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002966-11 Sponsor Protocol Number: 116427 Start Date*: 2013-02-22
    Sponsor Name:GlaxoSmithKline
    Full Title: A phase II/III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the immunogenicity and safety of GSK Biologicals? herpes zoster HZ/su candidate vaccine when ad...
    Medical condition: Herpes Zoster and related complications
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    14.1 10021881 - Infections and infestations 10019972 Herpes viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-003835-20 Sponsor Protocol Number: ALN-TTRSC-004 Start Date*: 2014-11-26
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyl...
    Medical condition: Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10016202 Familial amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023801-36 Sponsor Protocol Number: RVX222-CS-007 Start Date*: 2011-09-26
    Sponsor Name:Resverlogix Corp.
    Full Title: Phase IIb multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial for the assessment of coronary plaque changes with RVX000222, as determined by intravascular ultr...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001630-21 Sponsor Protocol Number: BAY59-7939/39039039STM4001/18262 Start Date*: 2015-12-15
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
    Medical condition: Venous thromboembolism (VTE)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006624-19 Sponsor Protocol Number: AVF3671g Start Date*: 2007-11-19
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIIb TRIAL COMPARING BEVACIZUMAB THERAPY WITH OR WITHOUT ERLOTINIB AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB FOR THE FIRST-LINE TREATM...
    Medical condition: Non-small-cell-lung-cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) BG (Prematurely Ended) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000550-12 Sponsor Protocol Number: NRL920-01/2008 (IBSc) Start Date*: 2008-11-06
    Sponsor Name:Norgine Pharmaceuticals Ltd
    Full Title: A Phase IIIb/IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Movicol® with Placebo in Patients with Constipation Associated...
    Medical condition: Constipation associated with Irritable Bowel Syndrome (IBS-C).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010774 Constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-003304-12 Sponsor Protocol Number: A0081279 Start Date*: 2013-02-12
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A Randomized Double Blind Placebo Controlled Parallel Group Study of the Efficacy and Safety of Pregabalin (BID) in Subjects with Post-Traumatic Peripheral Neuropathic Pain
    Medical condition: Chronic post-traumatic peripheral neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) BG (Completed) HU (Completed) BE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-007025-51 Sponsor Protocol Number: 12279A Start Date*: 2008-10-28
    Sponsor Name:H. Lundbeck A/S
    Full Title: A randomised, double-blind, parallel-group, placebo-controlled and active-referenced study evaluating the efficacy and safety of three fixed dose regimens of Lu AA34893 in the treatment of Major De...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) FR (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013053-15 Sponsor Protocol Number: MK-7009, PN028 Start Date*: 2010-05-31
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl...
    Medical condition: Hepatitis C virus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) BE (Completed) DE (Completed) AT (Completed) GB (Completed) LT (Completed) ES (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003702-41 Sponsor Protocol Number: IDR-OM-02 Start Date*: 2018-07-03
    Sponsor Name:Soligenix UK Limited
    Full Title: A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for...
    Medical condition: Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Ongoing) ES (Completed) HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005588-29 Sponsor Protocol Number: 1487-0001 Start Date*: 2021-05-12
    Sponsor Name:SCS Boehringer Ingelheim Comm. V
    Full Title: A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of sympt...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DK (Completed) NL (Prematurely Ended) PT (Completed) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003503-39 Sponsor Protocol Number: ABR54654 Start Date*: 2016-07-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
    Medical condition: Individuals at Ultra High Risk for Psychosis
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) IT (Completed) ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-005771-39 Sponsor Protocol Number: RVLO221-02 Start Date*: 2023-03-16
    Sponsor Name:Revolo Biotherapeutics Ltd
    Full Title: A Phase 2, randomised, double-blind, placebo-controlled, dose escalation study to investigate the effects of IRL201805 in participants with moderately to severely active rheumatoid arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002397-27 Sponsor Protocol Number: MK-2060-007 Start Date*: 2021-11-12
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Pat...
    Medical condition: Prevention of arteriovenous graft thrombosis in patients with end stage renal disease receiving hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10053182 Arteriovenous graft thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2022-000169-42 Sponsor Protocol Number: KPL-404-C211 Start Date*: 2022-10-28
    Sponsor Name:Kiniksa Pharmaceuticals, Ltd.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects with Moderate to Severe, Active Rheumatoid Art...
    Medical condition: Rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005872-29 Sponsor Protocol Number: MORAb-003-004 Start Date*: 2009-09-24
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Plati...
    Medical condition: First relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) FR (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021082-74 Sponsor Protocol Number: U31287-A-U201 Start Date*: 2011-01-21
    Sponsor Name:DAIICHI SANKYO DEVELOPMENT LTD.
    Full Title: RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH ERLOTINIB IN EGFR TREATMENT NAÏVE SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WH...
    Medical condition: Treatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) LT (Completed) HU (Completed) GB (Completed) BG (Completed) AT (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002806-31 Sponsor Protocol Number: 20120230(KAI-4169-007) Start Date*: 2013-02-12
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease ...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    14.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) IT (Completed) ES (Completed) SE (Completed) HU (Completed) PL (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001230-42 Sponsor Protocol Number: CTKI258A2210 Start Date*: 2012-03-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ bre...
    Medical condition: Breast cancer, HER2 negative and HR positive, with evidence of disease progression after prior endocrine therapy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed) ES (Completed) HU (Completed) BE (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 235  236  237  238  239  240  241  242  243  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 19:06:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA